PMID:31536259
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
Choose Wisely: Opt for drinks lower in alcohol and sugar content
It may be used in controlled research settings for comparative evaluation of receptor activity, ligand-receptor interaction, and related analytical studies
Advertisement I think what youre going to start seeing is new products being introduced to the market that actually have less of those side effects, which then would be more advantageous for athletes, said Matthew Fedoruk, the chief science officer at the U.S
Diabetes Care 2019;42:S90-S102